{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:08:41Z","timestamp":1790208521896,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["2019\\u221223822"],"award-info":[{"award-number":["2019\\u221223822"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.dld.2024.06.033","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T17:34:46Z","timestamp":1720805686000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["CT-based radiogenomics of intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4108-4832","authenticated-orcid":false,"given":"Luca","family":"Vigan\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zanuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3932-1330","authenticated-orcid":false,"given":"Francesco","family":"Fiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2336-0176","authenticated-orcid":false,"given":"Luca","family":"Cerri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Laino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-053X","authenticated-orcid":false,"given":"Angela","family":"Ammirabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1043-8690","authenticated-orcid":false,"given":"Elisa Maria","family":"Ragaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Maria","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Francone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-1983","authenticated-orcid":false,"given":"Francesca","family":"Ieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Di Tommaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2024.06.033_bib0001","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.06.033_bib0002","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0003","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","article-title":"Systemic therapies for intrahepatic cholangiocarcinoma","volume":"72","author":"Kelley","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.06.033_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.dld.2024.06.033_bib0005","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.06.033_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100505","article-title":"Role of molecular genetics in the clinical management of cholangiocarcinoma","volume":"7","author":"Normanno","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.dld.2024.06.033_bib0007","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0008","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0009","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/j.annonc.2022.04.443","article-title":"O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0010","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0011","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0012","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0013","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0014","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.dld.2024.06.033_bib0015","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0016","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2217\/fon-2022-0214","article-title":"Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial","volume":"18","author":"Ohba","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0017","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0018","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/1078-0432.CCR-23-1926","article-title":"Comparative genomic analysis and clinical outcomes of BRAF-mutated advanced biliary tract cancers","volume":"29","author":"Tang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2024.06.033_bib0019","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0020","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1200\/JCO.2021.39.15_suppl.3108","article-title":"Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer","volume":"39","author":"Hong","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0022","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0023","doi-asserted-by":"crossref","first-page":"14744","DOI":"10.18632\/oncotarget.4539","article-title":"Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies","volume":"6","author":"Brandi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.dld.2024.06.033_bib0024","doi-asserted-by":"crossref","first-page":"14957","DOI":"10.18632\/oncotarget.14844","article-title":"Intratumoral heterogeneity of intrahepatic cholangiocarcinoma","volume":"8","author":"Walter","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.dld.2024.06.033_bib0025","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0026","article-title":"Radiomics of biliary tumors: a systematic review of current evidence","volume":"12","author":"Fiz","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.dld.2024.06.033_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132953","article-title":"Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes","volume":"10","author":"Sadot","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2024.06.033_bib0028","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1038\/s41598-021-86497-4","article-title":"Value of contrast-enhanced CT texture analysis in predicting IDH mutation status of intrahepatic cholangiocarcinoma","volume":"11","author":"Zhu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.dld.2024.06.033_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000910","article-title":"Machine learning: an approach to preoperatively predict PD-1\/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers","volume":"5","author":"Zhang","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.dld.2024.06.033_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104146","article-title":"Diagnosis and treatment of cholangiocarcinoma in Italy: a delphi consensus statement","volume":"192","author":"Rimassa","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.dld.2024.06.033_bib0031","article-title":"Contrast Administration impacts CT-based radiomics of colorectal liver metastases and non-tumoral liver parenchyma revealing the \"radiological\" tumour microenvironment","volume":"11","author":"Fiz","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.dld.2024.06.033_bib0032","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","article-title":"LIFEx: A freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity","volume":"78","author":"Nioche","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.dld.2024.06.033_bib0033","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.dld.2024.06.033_bib0034","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1007\/s00259-022-05765-1","article-title":"PET\/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival","volume":"49","author":"Fiz","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.dld.2024.06.033_bib0035","article-title":"A robust FISH assay to detect FGFR2 translocations in intrahepatic cholangiocarcinoma patients","volume":"13","author":"Zhang","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.dld.2024.06.033_bib0036","first-page":"1355","article-title":"Molecular detection of FGFR2 rearrangements in resected intrahepatic cholangiocarcinomas: FISH could be an ideal method in patients with histological small duct subtype","volume":"11","author":"Zou","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.dld.2024.06.033_bib0037","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.1007\/s00330-021-07926-6","article-title":"Preoperative prediction of postsurgical outcomes in mass-forming intrahepatic cholangiocarcinoma based on clinical, radiologic, and radiomics features","volume":"31","author":"Park","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.dld.2024.06.033_bib0038","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1007\/s00330-019-06142-7","article-title":"A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma","volume":"29","author":"Ji","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.dld.2024.06.033_bib0039","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/apt.16563","article-title":"Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma","volume":"54","author":"Harding-Theobald","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2024.06.033_bib0040","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s00330-021-08146-8","article-title":"Radiomic machine learning for predicting prognostic biomarkers and molecular subtypes of breast cancer using tumor heterogeneity and angiogenesis properties on MRI","volume":"32","author":"Lee","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.dld.2024.06.033_bib0041","first-page":"15","article-title":"Radiomic analysis of intrahepatic cholangiocarcinoma: non-invasive prediction of pathology data: a multicenter study to develop a clinical-radiomic model","author":"Fiz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2024.06.033_bib0042","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1007\/s00330-021-07793-1","article-title":"Radiomics signature on dynamic contrast-enhanced MR images: a potential imaging biomarker for prediction of microvascular invasion in mass-forming intrahepatic cholangiocarcinoma","volume":"31","author":"Zhou","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.dld.2024.06.033_bib0043","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fonc.2018.00360","article-title":"Novel nomogram for preoperative prediction of early recurrence in intrahepatic cholangiocarcinoma","volume":"8","author":"Liang","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.dld.2024.06.033_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11185451","article-title":"Functional investigation of the tumoural heterogeneity of intrahepatic cholangiocarcinoma by in vivo PET-CT navigation: a proof-of-concept study","volume":"11","author":"Vigan\u00f2","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2024.06.033_bib0045","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s10278-023-00799-9","article-title":"Mapping tumor heterogeneity via local entropy assessment: making biomarkers visible","volume":"36","author":"Costa","year":"2023","journal-title":"J Digit Imaging"},{"key":"10.1016\/j.dld.2024.06.033_bib0046","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/jnci\/djaa017","article-title":"Radiomics response signature for identification of metastatic colorectal cancer sensitive to therapies targeting EGFR pathway","volume":"112","author":"Dercle","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.dld.2024.06.033_bib0047","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2018-316407","article-title":"Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab","volume":"69","author":"Dohan","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.06.033_bib0048","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824008442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824008442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:34:30Z","timestamp":1778621670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865824008442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1590865824008442"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.06.033","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CT-based radiogenomics of intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}